XLV Jan 2020 76.000 call

OPR - OPR Delayed Price. Currency in USD
18.75
0.00 (0.00%)
As of 3:44PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close18.75
Open18.75
Bid14.05
Ask18.00
Strike76.00
Expire Date2020-01-17
Day's Range18.75 - 18.75
Contract RangeN/A
Volume1
Open Interest21
  • Health care coverage costs are on the rise: RPT
    Yahoo Finance Video

    Health care coverage costs are on the rise: RPT

    It’s no secret that health care costs continue to rise, but new research from the Commonwealth Fund indicates that Americans are paying more for their premiums and deductibles than ever before. Yahoo Finance's Adriana Belmonte breaks the report down with Zack Guzman and Kristin Myers, along with Payne Capital Management Financial Advisor, Courtney Dominguez.

  • Market Recap: Friday, November 15
    Yahoo Finance Video

    Market Recap: Friday, November 15

    The S&P 500, Dow and Nasdaq closed at record highs, ending the week on a high note as the Dow cleared 28,000 points for the first time ever.

  • Healthcare stocks rally
    Yahoo Finance Video

    Healthcare stocks rally

    Healthcare stocks rally and helped to lift the Dow. Yahoo Finance’s Scott Gamm, at the NYSE, covers why Healthcare stocks saw these huge gains.

  • Nurses are burning out at an alarming rate: Survey
    Yahoo Finance Video

    Nurses are burning out at an alarming rate: Survey

    A new survey out from AMN Healthcare has found an alarming rate of burnout among nurses, with almost a quarter working two nursing jobs at a time. Yahoo Finance's Adriana Belmonte joins Zack Guzman and Sibile Marcellus, along with CampusReform.org Editor-In-Chief Cabot Phillips, to discuss.

  • MarketWatch

    Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus

    Eli Lilly & Co. said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result of increased demand for its medicines and for the production of additional capacity for future medicines, and are helped by having more capital available as a result of tax reform. "These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," said Myles O'Neill, president of manufacturing operations. "All of these projects support Lilly's investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics." The stock, which was still inactive in premarket trading, has slipped 0.5% year to date, while the SPDR Health Care Select Sector ETF has climbed 13.0% and the S&P 500 has advanced 24.5%.

  • MarketWatch

    Merck raises quarterly dividend, to yield more than peers and the S&P 500

    Shares of Merck & Co. Inc. were up 0.3% in midday trading Tuesday, after the health care company said it will raise its quarterly dividend by 11%. The company will pay a dividend of 61 cents a share, up from 55 cents a share, on Jan. 8 to shareholders or record on Dec. 16. Based on the current stock price, the new annual dividend rate would imply a dividend yield of 2.89%, compared with the yield for the SPDR Health Care Select Sector ETF of 1.54% and the implied yield for the S&P 500 of 1.90%. Merck's stock has slipped 2.1% over the past three months, while the health care ETF has gained 6.7%, the S&P 500 has tacked on 6.7% and the Dow Jones Industrial Average has advanced 6.9%.

  • Big Buying in Software and Biotech Stocks Is Bullish
    Investopedia

    Big Buying in Software and Biotech Stocks Is Bullish

    While the market will eventually need to vent and pull back, buyers remain in control, with buying in software and biotech.

  • MarketWatch

    UnitedHealth's stock rallies to pace the Dow's gainers, after SunTrust boosts price target

    Shares of UnitedHealth Group Inc. rallied 2.2% in morning trading Monday, enough to pace the Dow Jones Industrial Average's gainers, after analyst David MacDonald at SunTrust Robinson Humphrey raised raised his price target to the highest on the Street. The managed care company's stock price gain was adding about 40 points to the Dow's price, while the Dow was down 11 points. MacDonald reiterated his buy rating on UnitedHealth's stock and raised his price target to $335 from $310, which makes him the most bullish of the 26 analysts surveyed by FactSet. "We have raised managed care price targets following the release of Senator Warren's plans to implement Medicare For All, which we think provide additional clarity and likely allays some concerns," MacDonald wrote in a note to clients. "We remain bullish on managed care and continue to view the companies as a key part of the healthcare cost solutions." Among price target increases, shares of WellCare Health Plans Inc. rose 2.4%, Humana Inc. tacked on 0.6%, Anthem Inc. hiked up 1.9%, Molina Healthcare Inc. tacked on 3.1% and CVS Health Inc. advanced 0.7% and Molina Healthcare Inc. rallied 3.1%.

  • MarketWatch

    Health stocks post best day in 10 months as Trump announces transparency rules

    A popular exchange-traded fund that tracks the health-care sector saw its best daily return in 10 months on Friday after the Trump administration proposed new rules aimed at making health-care prices more transparent. The SPDR Health Care Select Sector ETF posted a 2.1%, marking its best day since Jan. 4, when it rose 2.98%, according to FactSet data. The Trump administration proposed a rule that would require health insurers to disclose estimated out-of-pocket costs, including negotiated rates, to patients in advance of a procedure or office visit. It also finalized a rule requiring hospitals to make transparent the prices they charge patients starting in 2021. It's possible that the stocks gained on doubts on how the rules would be enforced. "While the Trump administration's new hospital price transparency requirement is quite sweeping, the enforcement of it is quite weak - a maximum fine of $300 per day," Kaiser Family Foundation executive Larry Levitt wrote on Twitter. Shares of UnitedHealth Group Inc. , which is the largest health insurer in the U.S., and Anthem Inc. each rose roughly 5%. Shares of Tenet Healthcare Corp. and HCA Healthcare Inc. , both large hospital operators, were up at least 2%. The S&P 500 is up 24.4% year-to-date.

  • MarketWatch

    Abbott Laboratories CEO Miles White to step down after 2 decades in charge

    Abbott Laboratories said Wednesday that Chief Executive Miles White will step down on March 31, 2020, after 21 years in the role. White, who joined Abbott in 1984, will remain executive chairman. The healthcare company said Robert Ford, who has been chief operating officer since October 2018 and a 23-year Abbott veteran, will succeed White as CEO. Abbott's stock slipped 0.3% in premarket trading. It has rallied 21.4% over the past 12 months through Tuesday, while the SPDR Health Care Select Sector ETF has gained 4.7% and the S&P 500 has advanced 13.6%.

  • Follow Morgan Stanley to Trade 2020 Election With ETFs
    Zacks

    Follow Morgan Stanley to Trade 2020 Election With ETFs

    Morgan Stanley outlined four outcomes of the 2020 election and its strategies for investors on how to make the most of them.

  • MarketWatch

    Thermo Fisher sets new $2.5 billion stock buyback program

    Thermo Fisher Scientific Inc. announced Friday a new $2.5 billion stock repurchase program, with no expiration date. The analytical instruments and patient diagnostics company's new program replaces the current authorization, which had $500 million remaining. Based on Thursday's stock closing price of $293.54, the new program would allow for the repurchase of up to 8.5 million shares, or about 2.1% of the shares outstanding. The stock rose 0.3% in premarket trading. It has run up 31.2% year to date through Thursday, while the SPDR Health Care Select Sector ETF has gained 9.2% and the S&P 500 has rallied 23.1%.

  • Global Investment Presents Opportunity
    Investopedia

    Global Investment Presents Opportunity

    While U.S. markets pause, there could be opportunities in international investments, and health care stocks are becoming more attractive.

  • MarketWatch

    Humana's stock jumps after profit and revenue beat expectations, upbeat outlook

    Shares of Humana Inc. rallied 2.1% in premarket trading Wednesday, after the health care services company reported third-quarter profit and revenue that beat expectations, and provided an upbeat outlook. Net income was $888 million, or $5.14 a share, compared with $901 million, or $4.65 a share, in the year ago period. Excluding non-recurring items, adjusted EPS rose to $5.03 from $4.58, above the FactSet consensus of $4.58. Revenue rose to $16.24 billion from $14.21 billion, to beat the FactSet consensus of $16.15 billion, boosted by strength in its Medicare Advantage and healthcare services businesses. For 2019, Humana raised its adjusted EPS guidance to "approximately" $17.75, which is above the FactSet consensus of $17.64, and its expected individual Medicare Advantage membership growth outlook to about 530,000 members from the previous range of 480,000 to 500,000 members. The stock has gained 2.9% year to date through Tuesday, while the S&P 500 has rallied 22.7%.

  • Elizabeth Warren says ‘Medicare for All’ won’t mean higher taxes for middle class
    MarketWatch

    Elizabeth Warren says ‘Medicare for All’ won’t mean higher taxes for middle class

    Elizabeth Warren on Friday explains how she proposes to pay for her “Medicare for All” plan, after drawing criticism from her primary opponents for refusing to say whether her plan would raise taxes on the middle class.

  • Two Trending healthcare stocks with a strong pulse.
    Yahoo Finance

    Two Trending healthcare stocks with a strong pulse.

    The SPDR Healthcare Sector fund ETF (XLV) has been the best performing sector ETF in the last month with a 4.65% return. This earnings season has been relatively positive for Healthcare stocks.

  • MarketWatch

    AbbVie beats earnings expectations and raises outlook, boosts dividend by 10%

    AbbVie Inc. reported Friday a third-quarter adjusted profit and revenue that rose above expectations, helped by strength in its immunology and oncology business segments, and raised its earnings outlook. The stock slipped 0.4% in premarket trading. The company also raised its quarter dividend by 10% to $1.18 a share from $1.07 a share. Net income fell to $1.88 billion, or $1.26 a share, from $2.75 billion, or $1.81 a share, in the year-ago period. Excluding non-recurring items, such as an impairment charge, adjusted EPS rose to $2.33 from $2.14, above the FactSet consensus of $2.30. Revenue grew 3.0% to $8.48 billion, topping the FactSet consensus of $8.38 billion. Among AbbVie's best selling drugs, Humira revenue grew 3.7% to $4.94 billion to beat the FactSet consensus of $4.89 billion and Imbruvica revenue increased 29% to $1.26 billion, above expectations of $1.19 billion. AbbVie raised its 2019 adjusted EPS guidance range to $8.90 to $8.92 from $8.82 to $8.92. The new dividend will be payable Feb. 14 to shareholders of record on Jan. 15. Based on Thursday's stock closing price of $79.55, the new annual dividend rate implies a dividend yield of 5.93%, compared with the yield for the SPDR Health Care Select Sector ETF of 1.58% and the implied yield for the S&P 500 of 1.95%.

  • MarketWatch

    McKesson matches profit expectations, but sales rise well above forecasts

    McKesson Corp. reported Wednesday a fiscal second-quarter profit that matched expectations while revenue rose well above expectations, amid strength in its U.S. pharmaceutical and specialty solutions business. The stock was still inactive in premarket trading. For the quarter to Sept. 30, the health care and drug company swung to net loss of $730 million, or $3.99 a share, from income of $499 million, or $2.52 a share, in the year-ago period. Excluding non-recurring items, such as a $1.4 billion charge related to an impairment with the planned exit of its investment in Change Healthcare, adjusted EPS came to $3.60, which matched the FactSet consensus. Revenue rose 9% to $57.62 billion, above the FactSet consensus of $55.08 billion. U.S. pharmaceutical and specialty solutions revenue grew 10% to $46.0 billion, primarily because of price increases in branded pharmaceuticals and increased specialty pharmaceutical volume. European pharmaceutical revenue fell 1% to $6.6 billion and medical-surgical revenue increased 6% to $2.1 billion. The company affirmed its fiscal 2020 adjusted EPS guidance range of $14.00 to $14.60, which surrounds the FactSet consensus of $14.38. The stock has rallied 35.2% year to date, while the SPDR Health Care Select Sector ETF has advanced 9.0% and the S&P 500 has gained 21.1%.

  • MarketWatch

    Merck's stock rallies after profit and sales rise above expectations, full-year outlook raised

    Shares of Merck & Co. Inc. rallied 2.2% in premarket trading Tuesday, after the health care company reported a third-quarter profit and revenue that rose above expectations, and lifted its full-year outlook. Net income was $1.90 billion, or 74 cents a share, after $1.95 billion, or 73 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS rose to $1.51 from $1.19, beating the FactSet consensus of $1.24. Sales grew 15% to $12.40 billion, above the FactSet consensus of $11.64 billion, as sales of its top-selling cancer treatment Keytruda increased 62% to $3.07 billion to top forecasts of $2.87 billion. Animal Health revenue rose 10% to $1.1 billion, matching expectations. For 2019, Merck raised its guidance ranges for adjusted EPS to $5.12 to $5.17 from $4.84 to $4.94 and for revenue to $46.5 billion to $47.0 billion from $45.2 billion to $46.2 billion. The stock has gained 7.6% year to date through Monday, while the SPDR Health Care Select Sector ETF has advanced 7.5% and the Dow Jones Industrial Average has rallied 16.1%.

  • MarketWatch

    Danaher's stock drops after downbeat outlook offsets profit beat

    Shares of Danaher Corp. fell 1.6% in premarket trading Thursday, after the medical technology and products company beat profit and revenue expectations, but provided a downbeat earnings outlook. Net income fell to $648.4 million or 89 cents a share, from $663.7 million, or 93 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew 5.5% to $1.16 to top the FactSet consensus of $1.15. Sales increased to $5.04 billion from $4.85 billion, above the FactSet consensus of $5.02 billion. The company expects fourth-quarter adjusted EPS of $1.32 to $1.35, below the FactSet consensus of $1.37, and trimmed its 2019 guidance range to $4.74 to $4.77, after raising it to $4.75 to $4.80 in July. The stock has run up 34.3% year to date through Wednesday, while the SPDR Health Care Select Sector ETF has gained 6.8% and the S&P 500 has rallied 19.9%.

  • Top-Ranked Sector ETFs to Buy for Q4
    Zacks

    Top-Ranked Sector ETFs to Buy for Q4

    These sectors have a solid Zacks Rank and put the spotlight on these ETFs.

  • What's in Store for Healthcare ETFs in Q3 Earnings?
    Zacks

    What's in Store for Healthcare ETFs in Q3 Earnings?

    With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.

  • MarketWatch

    McKesson, Cardinal Health, AmerisourceBergen stocks surge after WSJ report of $18 billion settlement talks

    Shares of McKesson Corp. rallied 5.7% in midday trading Wednesday, enough to pace all of its larger-capitalization health care peers, after The Wall Street Journal reported that the drug distributor, and two others, were in talks to pay $18 billion to settle all litigation brought by state and local governments blaming the companies for fueling the opioid crisis. Of the other two drug distributors, shares of AmerisourceBergen Corp. climbed 4.7% and Cardinal Health Inc. hiked up 3.7%. Shares of Johnson & Johnson rose 2.4% after the WSJ report out late Tuesday, citing people familiar with the situation, said the company was also involved in the discussions to contribute additional money. The four companies' stocks topped the list of gainers in the SPDR Health Care Select Sector ETF , which inched up 0.1%, while the S&P 500 slipped 0.2%.

  • Healthcare ETFs to Buy on UnitedHealth's Solid Q3 Earnings
    Zacks

    Healthcare ETFs to Buy on UnitedHealth's Solid Q3 Earnings

    Investors could tap the company's strong growth story with ETFs having the largest allocation to this health insurance giant.